Jefferies Group LLC Reiterates $7.00 Price Target for NewLink Genetics Corporation (NLNK)
Other research analysts have also issued research reports about the company. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corporation and gave the company a buy rating in a report on Thursday, May 4th. ValuEngine lowered NewLink Genetics Corporation from a hold rating to a sell rating in a report on Friday, June 2nd. Robert W. Baird lowered NewLink Genetics Corporation from an outperform rating to a neutral rating and dropped their target price for the company from $25.00 to $8.00 in a report on Thursday, June 8th. Finally, Zacks Investment Research lowered NewLink Genetics Corporation from a hold rating to a sell rating in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. NewLink Genetics Corporation currently has an average rating of Hold and an average target price of $18.17.
NewLink Genetics Corporation (NASDAQ:NLNK) opened at 6.66 on Friday. The company’s market capitalization is $195.94 million. The company has a 50 day moving average of $7.06 and a 200 day moving average of $13.17. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17.
NewLink Genetics Corporation (NASDAQ:NLNK) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million for the quarter, compared to analyst estimates of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. On average, equities analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Jefferies Group LLC Reiterates $7.00 Price Target for NewLink Genetics Corporation (NLNK)” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/08/28/jefferies-group-llc-reiterates-7-00-price-target-for-newlink-genetics-corporation-nlnk.html.
Several hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC increased its stake in NewLink Genetics Corporation by 2.8% in the fourth quarter. Teachers Advisors LLC now owns 201,807 shares of the biotechnology company’s stock worth $2,075,000 after buying an additional 5,500 shares during the period. First Mercantile Trust Co. acquired a new stake in NewLink Genetics Corporation during the first quarter worth $143,000. Russell Investments Group Ltd. acquired a new stake in NewLink Genetics Corporation during the first quarter worth $978,000. Wells Fargo & Company MN increased its stake in NewLink Genetics Corporation by 3.0% in the first quarter. Wells Fargo & Company MN now owns 162,926 shares of the biotechnology company’s stock worth $3,926,000 after buying an additional 4,701 shares during the period. Finally, C WorldWide Group Holding A S acquired a new stake in NewLink Genetics Corporation during the first quarter worth $261,000. Hedge funds and other institutional investors own 54.78% of the company’s stock.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.